{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T16:15:37Z","timestamp":1695831337468},"reference-count":9,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":3858,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[1998,10]]},"abstract":"<jats:p><jats:bold>Zusammenfassung. <\/jats:bold> Kontiniuerliche H\u00e4mofiltrations\u2010(CAVH, CVVH) und H\u00e4modialyse\u2010verfahren (CAVHD, CVVHD) werden zunehmend bei Patienten mit akutem Nierenversagen (ARF) eingesetzt. Zwischen den einzelnen Verfahren bestehen deutliche Unterschiede hinsichtlich der Elimination von Fluconazol aus dem Plasma*. Diese ist bei CVVHD, abh\u00e4ngig von der Dialysat\u2010 und Ultrafiltratflu\u00dfrate, im Gegensatz zur CVVH und der intermittierenden H\u00e4modialyse am st\u00e4rksten ausgepr\u00e4gt, wobei die Fluconazol\u2010Clearance bei CVVHD 2 L\/h sogar \u00fcber derjenigen von Gesunden liegen kann. Um unter kontinuierlichen Verfahren therapeutische Fluconazol\u2010Plasmaspiegei zu erreichen, sollte initial die gleiche Anfangsdosis wie bei nierengesunden Patienten appliziert werden, gefolgt von der auf die H\u00e4lfte reduzierten Erhaltungsdosis, wie sie f\u00fcr Patienten mit einer eingeschr\u00e4nkten Kreatinin\u2010Clearance von bis zu 11 ml\/min vorgesehen ist. Aufgrund theoretischer \u00dcberlegungen wird diese halbe Erhaltungsdosis je nach gew\u00e4hltem Verfahren mit einem Faktor multipliziert, der das Ausma\u00df der extrakorporalen Elimination der verabreichten Wirkstoffmenge ber\u00fccksichtigt (CAVH, CVVH: x2,2 bei einer Ultrafiltratflu\u00dfrate von 0,5 L\/h; CAVHD, CVVHD: x3,8 bei einer kombinierten Dialysat\u2010\/Ultrafiltratflu\u00dfrate von 1,5 L\/h). Um subtherapeutische Plasmaspiegel bei vitalen Indikationen zu*** vermeiden, empfiehlt sich \u2010 auch im Hinblick auf die geringe Anzahl einschl\u00e4giger Untersuchungen mit relativ niedrigen Dosierungen bis zu 200 mg\/die \u2010 die Messung der Plasma(tal)spiegel von Fluconazol.<\/jats:p><jats:p><jats:bold>Summary. <\/jats:bold> Continuous haemofiltration (CAVH, CVVH) and haemodialysis (CAVHD, CVVHD) are increasingly used in patients with acute renal failure (ARF). The elimination rates of fluconazole vary considerably among the different procedures*. In CVVHD, the elimination rate is, depending on the combined dialysate\/ultrafiltrate flow rate, the most marked compared to CVVH and intermittent dialysis with a fluconazole clearance exceeding the values of healthy persons in CVVHD 2 L\/h. To achieve therapeutic plasma levels during continuous renal replacement therapy, the same loading dose as in patients without renal failure should be applied, followed by the adjusted maintenance dose for anuric patients multiplied by a factor taking the extracorporeal elimination of the absorbed dose into account (CAVH, CVVH: x2.2, ultrafiltrate flow 0.5 L\/h; CAVHD, CVVH: x3.8, combined dialysate \/ ultrafiltrate flow 1.5 L\/h). Despite the broad therapeutic margin of fluconazole, drug monitoring is recommended with respect to the very limited number of in\u2010***<\/jats:p>","DOI":"10.1111\/j.1439-0507.1998.tb00610.x","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T16:55:50Z","timestamp":1240592150000},"page":"86-88","source":"Crossref","is-referenced-by-count":5,"title":["Pharmakokinetik und Dosierung von Fluconazol bei kontinuierlichen H\u00e4mofiltrations\u2010 (CAVH, CVVH) und H\u00e4modialyseverfahren (CAVHD, CVVHD)"],"prefix":"10.1111","volume":"41","author":[{"given":"L.","family":"Pittrow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Penk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199324010-00002"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.5.695"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199324050-00002"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02570511"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1681\/ASN.V62242","article-title":"Pharmacokinetics of Fluconazole in renal failure.","volume":"6","author":"Berl T.","year":"1995","journal-title":"J Am Soc Nephrol."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018060-00006"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03623.x"},{"key":"e_1_2_1_9_2","first-page":"198","article-title":"Drug dosing during continuous arterio\u2010venous haemofiltration","volume":"7","author":"Bickley S. K.","year":"1988","journal-title":"Clin. Pharmacy"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265934"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.1998.tb00610.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.1998.tb00610.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:54:37Z","timestamp":1695704077000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.1998.tb00610.x"}},"subtitle":["Pharmacokinetics and dosage of fluconazole in continuous haemofiltration (CAVH, CVVH) and haemodialysis (CAVHD, CVVHD)"],"short-title":[],"issued":{"date-parts":[[1998,10]]},"references-count":9,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[1998,10]]}},"alternative-id":["10.1111\/j.1439-0507.1998.tb00610.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.1998.tb00610.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,10]]}}}